Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy.

Autor: Tang JP; Division of Pediatric Hematology-Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California., Peters CW; Division of Pediatric Hematology-Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California., Quiros C; Division of Pediatric Hematology-Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California., Wang X; Department of General Internal Medicine and Health Services Research, University of California, Los Angeles, California., Klomhaus AM; Department of General Internal Medicine and Health Services Research, University of California, Los Angeles, California., Yamada RE; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California., Timmerman JM; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California., Moore TB; Division of Pediatric Hematology-Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California., Nowicki TS; Division of Pediatric Hematology-Oncology, Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, California.; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, California.; Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, California.; Department of Microbiology, Immunology, and Molecular Genetics, University of California, Los Angeles, California.

Publikováno v: Cancer immunology research [Cancer Immunol Res] 2022 Dec 02; Vol. 10 (12), pp. 1433-1440.

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1 ^- HK2 ⁺ Multiple Myeloma.

Autor: Xu S; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles., Zhou T; Department of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, California., Doh HM; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles., Trinh KR; Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles., Catapang A; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles., Lee JT; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles., Braas D; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles.; UCLA Metabolomics Center, David Geffen School of Medicine, University of California, Los Angeles., Bayley NA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles., Yamada RE; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Vasuthasawat A; Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles., Sasine JP; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles.; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Timmerman JM; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles.; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Larson SM; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles.; Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles., Kim Y; Department of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, California., MacLeod AR; Department of Antisense Drug Discovery, Ionis Pharmaceuticals Inc., Carlsbad, California., Morrison SL; Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, University of California, Los Angeles.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles., Herschman HR; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles. hherschman@mednet.ucla.edu.; Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California, Los Angeles.; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles.; Department of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles.; Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles.

Publikováno v: Cancer research [Cancer Res] 2019 May 15; Vol. 79 (10), pp. 2748-2760. Date of Electronic Publication: 2019 Mar 18.

Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha.

Autor: Young PA; 1 Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California., Yamada RE; 1 Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California., Trinh KR; 2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California., Vasuthasawat A; 2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California., De Oliveira S; 3 Division of Pediatric Hematology & Oncology, Department of Pediatrics, University of California, Los Angeles, Los Angeles, California., Yamada DH; 2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California., Morrison SL; 2 Department of Microbiology, Immunology, and Molecular Genetics, University of California , Los Angeles, Los Angeles, California., Timmerman JM; 1 Division of Hematology & Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, California.

Publikováno v: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research [J Interferon Cytokine Res] 2018 Jun; Vol. 38 (6), pp. 239-254.